Medical Design Briefs - August 2024 - 16

How Advanced
Drug-Delivery Systems
Are Improving Healthcare
T
he administration of highdose
biologics presents
unique challenges and opportunities
for the development
of drug-delivery
systems. With the advent of innovative
reusable drug-delivery devices,
the landscape of patient adherence
and comfort is evolving significantly.
These advanced devices are designed
to handle higher concentrations
and viscosities of therapeutic
drugs, allowing for new routes of administration
that can be managed by
Bjarne Sørensen, Director of FrontEnd
Innovation, Phillips Medisize
patients themselves at home. In this Q&A, Bjarne Sørensen, director
of front-end innovation for Phillips Medisize, explores how
these technological advancements are transforming the administration
of biologics, while also focusing on patient adherence, cost
savings, and overall improvements in healthcare delivery.
MDB: How are innovative reusable drug-delivery device solutions
contributing to enhanced patient adherence and comfort
in the administration of high-dose biologics?
Bjarne Sørensen: New possibilities within formulations and
suspensions, implementing significantly higher concentrations
of therapeutic drug load, open new routes of administration for
biologics. When developing high-dose formulations, it is important
to consider the required flexibility from the possible
device solutions and determine the restrictions they impose on
formulation development.
The new possibility of reusable electromechanical devices can
enable the patient to self-administer injections with challenging
parameters such as high viscosity or higher injection volumes,
without any compromises on usability. The possible addition of
a connected system can add potential adherence support options
to the complete system.
MDB: Can you discuss the potential cost savings that highdose
formulations in biologics and their associated delivery devices
bring to the healthcare industry, particularly in terms of
reduced administration frequency and resource utilization?
Sørensen: The possibility of moving IV treatments from hospitals
or infusion clinics to home subcutaneous (SC) administration by
the patients will not only provide a substantial cost saving for healthcare
systems and payers, but very importantly also potentially improve
the quality of life for patients. The potential of increasing the
time between doses is an added benefit impacting cost of care.
16
MDB: How do high-dose formulations in biologics help in
reducing the frequency of administration, and what benefits
does this bring to patients and healthcare providers?
Sørensen: New high-dose formulation technologies can, beyond
the transition from IV to subcutaneous, also be a potential
opportunity for long-acting formulations. These technologies
can potentially extend the time between doses, and then
additionally reduce the negative impact on the patients. This
opportunity will naturally increase the previously mentioned
benefits for all the involved.
www.medicaldesignbriefs.com
Medical Design Briefs, August 2024
https://www.medicaldesignbriefs.com

Medical Design Briefs - August 2024

Table of Contents for the Digital Edition of Medical Design Briefs - August 2024

Medical Design Briefs - August 2024 - CvrFlap1
Medical Design Briefs - August 2024 - CvrFlap2
Medical Design Briefs - August 2024 - Cover1
Medical Design Briefs - August 2024 - Cover2
Medical Design Briefs - August 2024 - 1
Medical Design Briefs - August 2024 - 2
Medical Design Briefs - August 2024 - 3
Medical Design Briefs - August 2024 - 4
Medical Design Briefs - August 2024 - 5
Medical Design Briefs - August 2024 - 6
Medical Design Briefs - August 2024 - 7
Medical Design Briefs - August 2024 - 8
Medical Design Briefs - August 2024 - 9
Medical Design Briefs - August 2024 - 10
Medical Design Briefs - August 2024 - 11
Medical Design Briefs - August 2024 - 12
Medical Design Briefs - August 2024 - 13
Medical Design Briefs - August 2024 - 14
Medical Design Briefs - August 2024 - 15
Medical Design Briefs - August 2024 - 16
Medical Design Briefs - August 2024 - 17
Medical Design Briefs - August 2024 - 18
Medical Design Briefs - August 2024 - 19
Medical Design Briefs - August 2024 - 20
Medical Design Briefs - August 2024 - 21
Medical Design Briefs - August 2024 - 22
Medical Design Briefs - August 2024 - 23
Medical Design Briefs - August 2024 - 24
Medical Design Briefs - August 2024 - 25
Medical Design Briefs - August 2024 - 26
Medical Design Briefs - August 2024 - 27
Medical Design Briefs - August 2024 - 28
Medical Design Briefs - August 2024 - 29
Medical Design Briefs - August 2024 - 30
Medical Design Briefs - August 2024 - 31
https://www.nxtbook.com/smg/techbriefs/24MDB09
https://www.nxtbook.com/smg/techbriefs/24MDB08
https://www.nxtbook.com/smg/techbriefs/24MDB07
https://www.nxtbook.com/smg/techbriefs/24MDB06
https://www.nxtbook.com/smg/techbriefs/24MDB05
https://www.nxtbook.com/smg/techbriefs/24MDB04
https://www.nxtbook.com/smg/techbriefs/24MDB03
https://www.nxtbook.com/smg/techbriefs/24MDB02
https://www.nxtbook.com/smg/techbriefs/24MDB01
https://www.nxtbook.com/smg/techbriefs/23MDB12
https://www.nxtbook.com/smg/techbriefs/23MDB11
https://www.nxtbook.com/smg/techbriefs/23MDB10
https://www.nxtbook.com/smg/techbriefs/23MDB09
https://www.nxtbook.com/smg/techbriefs/23MDB08
https://www.nxtbook.com/smg/techbriefs/23MDB07
https://www.nxtbook.com/smg/techbriefs/23MDB06
https://www.nxtbook.com/smg/techbriefs/23MDB05
https://www.nxtbook.com/smg/techbriefs/23MDB04
https://www.nxtbook.com/smg/techbriefs/23MDB03
https://www.nxtbook.com/smg/techbriefs/23MDB02
https://www.nxtbook.com/smg/techbriefs/23MDB01
https://www.nxtbook.com/smg/techbriefs/techleaders22
https://www.nxtbook.com/smg/techbriefs/22MDB12
https://www.nxtbook.com/smg/techbriefs/22MDB11
https://www.nxtbook.com/smg/techbriefs/22MDB10
https://www.nxtbook.com/smg/techbriefs/22MDB09
https://www.nxtbook.com/smg/techbriefs/22MDB08
https://www.nxtbook.com/smg/techbriefs/22MDB07
https://www.nxtbook.com/smg/techbriefs/22MDB06
https://www.nxtbook.com/smg/techbriefs/22MDB04
https://www.nxtbook.com/smg/techbriefs/techleaders21
https://www.nxtbook.com/smg/techbriefs/22MDB03
https://www.nxtbook.com/smg/techbriefs/22MDB02
https://www.nxtbook.com/smg/techbriefs/22MDB01
https://www.nxtbook.com/smg/techbriefs/21MDB12
https://www.nxtbook.com/smg/techbriefs/21MDB11
https://www.nxtbook.com/smg/techbriefs/21MDB10
https://www.nxtbook.com/smg/techbriefs/21MDB09
https://www.nxtbook.com/smg/techbriefs/21MDB08
https://www.nxtbook.com/smg/techbriefs/21MDB07
https://www.nxtbook.com/smg/techbriefs/21MDB06
https://www.nxtbook.com/smg/techbriefs/21MDB05
https://www.nxtbook.com/smg/techbriefs/21MDB04
https://www.nxtbook.com/smg/techbriefs/21MDB02
https://www.nxtbookmedia.com